Rachid Abbas
Overview
Explore the profile of Rachid Abbas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saucier E, Bougeard G, Gomez-Mascard A, Schramm C, Abbas R, Berlanga P, et al.
Pediatr Blood Cancer
. 2024 Oct;
71(12):e31362.
PMID: 39387369
Purpose: Describe clinical characteristics and outcome of Li-Fraumeni syndrome (LFS)-associated osteosarcomas. Methods: TP53 germline pathogenic/likely pathogenic variant carriers diagnosed with osteosarcoma in France between 1980 and 2019 were identified via...
2.
Bastard P, Cozic N, Brion R, Gaspar N, Piperno-Neumann S, Cordero C, et al.
Pediatr Blood Cancer
. 2024 Apr;
71(7):e31029.
PMID: 38679845
Background: Previous studies have shown that neutrophil-to-lymphocyte (NLR) ratio at diagnosis and early lymphocytes recovery on doxorubicin-based chemotherapy, may impact the outcome in patients with osteosarcoma (OST). This study aimed...
3.
Bateman R, Smith J, Donohue M, Delmar P, Abbas R, Salloway S, et al.
N Engl J Med
. 2023 Nov;
389(20):1862-1876.
PMID: 37966285
Background: Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is a subcutaneously administered, fully human, anti-Aβ...
4.
Del Baldo G, Vennarini S, Toniutti M, Abbas R, Lorentini S, Piccirilli E, et al.
Front Oncol
. 2023 Oct;
13:1259403.
PMID: 37860194
Background: Germ cell tumors (GCT) account for a minority of central nervous system (CNS) malignancies, highly prevalent in adolescents and young adults. Despite their aggressive biological behavior, prognosis is excellent...
5.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris M, Serra A, et al.
N Engl J Med
. 2023 Apr;
388(14):1284-1295.
PMID: 37018492
Background: Immunotherapy with chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neuroblastoma. Methods: In...
6.
Del Baldo G, Carai A, Abbas R, Cacchione A, Vinci M, Di Ruscio V, et al.
Ther Adv Med Oncol
. 2022 Sep;
14:17588359221113693.
PMID: 36090803
Background: Diffuse intrinsic pontine glioma (DIPG) is a fatal disease with a median overall survival (OS) of less than 12 months after diagnosis. Radiotherapy (RT) still remains the mainstay treatment....
7.
Del Baldo G, Abbas R, De Ioris M, Di Ruscio V, Alessi I, Miele E, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804835
Background: Ewing sarcoma (ES) is a rare and aggressive pediatric cancer. Numerous studies have attempted to identify new prognostic biomarkers. The predictive value of serum LDH and CRP has not...
8.
De Ioris M, Fabozzi F, Lodi M, Vitali G, Pasquale M, Del Baldo G, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565372
The occurrence of cancer in newborns within the first 28 days of life is uncommon, with different clinical presentation from other age groups. Prenatal diagnosis is reported in about half...
9.
Marchais A, Marques Da Costa M, Job B, Abbas R, Drubay D, Piperno-Neumann S, et al.
Cancer Res
. 2022 Jan;
82(6):974-985.
PMID: 35078815
Significance: These findings indicate that the osteosarcoma microenvironment composition is a major feature to identify hard-to-treat patient tumors at diagnosis and define the biological pathways and potential actionable targets associated...
10.
Abbas R, Wason J, Michiels S, Le Teuff G
Pharm Stat
. 2021 Sep;
21(1):268-288.
PMID: 34496117
Phase II immuno-oncology clinical trials screen for efficacy an increasing number of treatments. In rare cancers, using historical control data is a pragmatic approach for speeding up clinical trials. The...